SG11202011454TA - Ex-vivo model of inflamed human skin and uses thereof for screening anti-inflammatory compounds - Google Patents
Ex-vivo model of inflamed human skin and uses thereof for screening anti-inflammatory compoundsInfo
- Publication number
- SG11202011454TA SG11202011454TA SG11202011454TA SG11202011454TA SG11202011454TA SG 11202011454T A SG11202011454T A SG 11202011454TA SG 11202011454T A SG11202011454T A SG 11202011454TA SG 11202011454T A SG11202011454T A SG 11202011454TA SG 11202011454T A SG11202011454T A SG 11202011454TA
- Authority
- SG
- Singapore
- Prior art keywords
- human skin
- vivo model
- inflammatory compounds
- screening anti
- inflamed human
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
- C12N5/0629—Keratinocytes; Whole skin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2301—Interleukin-1 (IL-1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2323—Interleukin-23 (IL-23)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Toxicology (AREA)
- Analytical Chemistry (AREA)
- Dermatology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1771020A FR3071508B1 (en) | 2017-09-26 | 2017-09-26 | EX VIVO MODEL OF INFLAMMED HUMAN SKIN AND ITS USES FOR THE SCREENING OF ANTI-INFLAMMATORY COMPOUNDS |
| PCT/EP2018/000448 WO2019063122A1 (en) | 2017-09-26 | 2018-09-25 | Ex-vivo model of inflamed human skin and uses thereof for screening anti-inflammatory compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202011454TA true SG11202011454TA (en) | 2020-12-30 |
Family
ID=60302404
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202011454TA SG11202011454TA (en) | 2017-09-26 | 2018-09-25 | Ex-vivo model of inflamed human skin and uses thereof for screening anti-inflammatory compounds |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20200347429A1 (en) |
| EP (1) | EP3688141B1 (en) |
| JP (1) | JP7199427B2 (en) |
| KR (1) | KR102665807B1 (en) |
| CA (1) | CA3075899A1 (en) |
| DK (1) | DK3688141T3 (en) |
| ES (1) | ES2933121T3 (en) |
| FR (1) | FR3071508B1 (en) |
| SG (1) | SG11202011454TA (en) |
| WO (1) | WO2019063122A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210151816A (en) | 2019-03-12 | 2021-12-14 | 이피엠 (아이피), 인코포레이티드 | Cannabinoid acid ester compositions and uses thereof |
| JP2020180068A (en) * | 2019-04-25 | 2020-11-05 | 日本コルマー株式会社 | Evaluation method of anti-inflammatory agent in which epidermal inflammatory response control by dermal fibroblasts is applied |
| EP3940058A1 (en) | 2020-07-16 | 2022-01-19 | Genoskin | Microfluidic system to control perfusion, diffusion and collection of molecules over long periods in an ex-vivo skin model |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE509095T1 (en) | 2008-05-28 | 2011-05-15 | Symrise Ag | HUMAN EX-VIVO SKIN MODEL |
| FR2990106B1 (en) * | 2012-05-03 | 2014-05-09 | Genoskin | SYSTEM FOR SURVIVAL MAINTENANCE AND TRANSPORT OF SKIN BIOSPSIES AND ITS APPLICATIONS |
| EP2885637B1 (en) | 2012-08-15 | 2016-11-30 | The Procter & Gamble Company | Use of human ex vivo skin model in a method of identifying modulators of skin inflammation |
| WO2014083099A1 (en) * | 2012-11-30 | 2014-06-05 | Leo Pharma A/S | A method of inhibiting the expression of il-22 in activated t-cells |
| WO2014182655A1 (en) * | 2013-05-06 | 2014-11-13 | Stiefel Laboratories, Inc. | Assay for screening a compound for the ability to modulate proinflammatory cytokine production in human skin |
-
2017
- 2017-09-26 FR FR1771020A patent/FR3071508B1/en active Active
-
2018
- 2018-09-25 JP JP2020516700A patent/JP7199427B2/en active Active
- 2018-09-25 CA CA3075899A patent/CA3075899A1/en active Pending
- 2018-09-25 DK DK18780025.5T patent/DK3688141T3/en active
- 2018-09-25 EP EP18780025.5A patent/EP3688141B1/en active Active
- 2018-09-25 US US16/650,492 patent/US20200347429A1/en active Pending
- 2018-09-25 SG SG11202011454TA patent/SG11202011454TA/en unknown
- 2018-09-25 WO PCT/EP2018/000448 patent/WO2019063122A1/en unknown
- 2018-09-25 KR KR1020207012237A patent/KR102665807B1/en active IP Right Grant
- 2018-09-25 ES ES18780025T patent/ES2933121T3/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020535402A (en) | 2020-12-03 |
| ES2933121T3 (en) | 2023-02-02 |
| WO2019063122A1 (en) | 2019-04-04 |
| KR20200057765A (en) | 2020-05-26 |
| US20200347429A1 (en) | 2020-11-05 |
| EP3688141A1 (en) | 2020-08-05 |
| CA3075899A1 (en) | 2019-04-04 |
| DK3688141T3 (en) | 2022-12-12 |
| EP3688141B1 (en) | 2022-11-09 |
| JP7199427B2 (en) | 2023-01-05 |
| FR3071508A1 (en) | 2019-03-29 |
| KR102665807B1 (en) | 2024-05-14 |
| FR3071508B1 (en) | 2022-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL270320B (en) | Cosmetic compositions for skin health and methods of using same | |
| IL249162B (en) | Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1 | |
| EP3468657A4 (en) | System for wireless recording and stimulating of bioelectric events | |
| PL3349783T3 (en) | Compositions and methods relating to the treatment of diseases | |
| IL243348A0 (en) | Combination therapy of antibodies against human csf-1r and antibodies against human pd-l1 | |
| IL249189A0 (en) | Combination therapy of antibodies activating human cd40 and antibodies against human pd-l1 | |
| IL265955A (en) | Therapeutic compounds and methods of use thereof | |
| EP3592227A4 (en) | Methods and systems to measure and evaluate stability of medical implants | |
| EP3169321A4 (en) | Propolis and extracts thereof for the treatment of skin cancers and improvement of skin health | |
| ZA201804660B (en) | Treatment of intrahepatic cholestasis and related liver diseases | |
| SG11202011454TA (en) | Ex-vivo model of inflamed human skin and uses thereof for screening anti-inflammatory compounds | |
| EP2949651A4 (en) | Substituted benzothiazoles and therapeutic uses thereof for the treatment of human diseases | |
| EP3713583A4 (en) | Methods and compositions for treatment of skin | |
| EP3062767A4 (en) | Skin care compositions and methods of use thereof | |
| EP3484526A4 (en) | Compositions and methods for treatment of cardiac diseases | |
| IL274433A (en) | Fulvestrant formulations and methods of their use | |
| IL270894A (en) | Human antibodies to bet v 1 and methods of use thereof | |
| GB201710822D0 (en) | Methods and medical uses relating to the treatment of hypoglycaemia | |
| SG11202004391QA (en) | Derivatives of ppd useful for coloring hair and skin | |
| EP3517537A4 (en) | Deuterated derivative of l-tetrahydropalmatine and medical use thereof | |
| EP3694545A4 (en) | Human pd-l1 antibodies and methods of use therefor | |
| EP3119387A4 (en) | Compositions for the treatment of dermatological diseases and disorders | |
| PL3515409T3 (en) | Complex and compositions for the treatment of ophthalmic and dermatological diseases | |
| EP3534932A4 (en) | Treatment of diseases related to igfb3 and its receptor | |
| ZA201800681B (en) | Adhesive composition and element for attaching to human skin |